Technical Analysis for MIRM - Mirum Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 180 Bearish Setup | Bearish Swing Setup | 3.32% | |
| Stochastic Reached Oversold | Weakness | 3.32% | |
| Oversold Stochastic | Weakness | 3.32% | |
| Fell Below 20 DMA | Bearish | 0.48% | |
| MACD Bearish Signal Line Cross | Bearish | 0.48% | |
| NR7 | Range Contraction | 0.48% | |
| Narrow Range Bar | Range Contraction | 0.48% | |
| Doji - Bullish? | Reversal | 0.48% | |
| Crossed Above 20 DMA | Bullish | -0.48% | |
| Outside Day | Range Expansion | -0.48% |
| Alert | Time |
|---|---|
| Rose Above Previous Day's High | 16 minutes ago |
| Up 3% | 16 minutes ago |
| 60 Minute Opening Range Breakout | 28 minutes ago |
| Up 2% | about 1 hour ago |
| Up 1% | about 1 hour ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2024
Mirum Pharmaceuticals, Inc., a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC). It is also developing Volixibat, an investigational oral inhibitor of ASBT, a protein that is primarily responsible for recycling bile acids from the intestine to the liver. The company was incorporated in 2018 and is based in Foster City, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Acid Recycling Liver Disease Hepatology Progressive Digestive Diseases Liver Bile Acid Primary Biliary Cholangitis Cholestasis Intrahepatic Cholestasis
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 35.56 |
| 52 Week Low | 23.14 |
| Average Volume | 494,011 |
| 200-Day Moving Average | 28.06 |
| 50-Day Moving Average | 25.47 |
| 20-Day Moving Average | 25.01 |
| 10-Day Moving Average | 25.13 |
| Average True Range | 1.08 |
| RSI (14) | 40.48 |
| ADX | 17.41 |
| +DI | 17.59 |
| -DI | 14.84 |
| Chandelier Exit (Long, 3 ATRs) | 23.75 |
| Chandelier Exit (Short, 3 ATRs) | 26.37 |
| Upper Bollinger Bands | 26.33 |
| Lower Bollinger Band | 23.69 |
| Percent B (%b) | 0.14 |
| BandWidth | 10.52 |
| MACD Line | -0.19 |
| MACD Signal Line | -0.12 |
| MACD Histogram | -0.061 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 25.26 | ||||
| Resistance 3 (R3) | 25.36 | 25.07 | 25.06 | ||
| Resistance 2 (R2) | 25.07 | 24.77 | 25.02 | 24.99 | |
| Resistance 1 (R1) | 24.57 | 24.58 | 24.43 | 24.47 | 24.93 |
| Pivot Point | 24.28 | 24.28 | 24.21 | 24.23 | 24.28 |
| Support 1 (S1) | 23.78 | 23.98 | 23.64 | 23.68 | 23.21 |
| Support 2 (S2) | 23.49 | 23.79 | 23.44 | 23.15 | |
| Support 3 (S3) | 22.99 | 23.49 | 23.08 | ||
| Support 4 (S4) | 22.89 |
